Literature DB >> 17172671

Long-term gene expression in dividing and nondividing cells using SV40-derived vectors.

David S Strayer1, Lokesh Agrawal, Pierre Cordelier, Bianling Liu, Jean-Pierre Louboutin, Elena Marusich, Hayley J McKee, Carmen N NiGongyi Ren, Marlene S Strayer.   

Abstract

Among the goals of gene therapy is long-term expression of delivered transgenes. Recombinant Tagdeleted SV40 vectors (rSV40s) are especially well suited for this purpose. rSV40s deliver transgene expression that endures for extended periods of time in tissue culture and in vivo, in both dividing and nondividing cells. These vectors are particularly effective in transducing some cell types that have been almost unapproachable using other gene delivery systems, such as quiescent hematopoietic progenitor cells and their differentiated derivatives. Other cellular targets include neurons, brain microglia, hepatocytes, dendritic cells, vascular endothelium, and others. Because rSV40s do not elicit neutralizing antibodies they are useful for in vivo gene delivery in settings where more than one administration may be desirable. The key characteristics of these vectors include their high production titers and therefore suitability for large cell pools, effectiveness in delivering intracellular proteins, and untranslated RNAs, maintenance of transgene expression at constant levels for extended times, suitability for constitutive or conditional promoters and for combinatorial gene delivery and ability to integrate into genomes of both dividing and nondividing cells.

Entities:  

Mesh:

Year:  2006        PMID: 17172671     DOI: 10.1385/MB:34:2:257

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.860


  102 in total

1.  Gene transfer with foamy virus vectors.

Authors:  Grant Trobridge; George Vassilopoulos; Neil Josephson; David W Russell
Journal:  Methods Enzymol       Date:  2002       Impact factor: 1.600

Review 2.  Separating fact from fiction: assessing the potential of modified adenovirus vectors for use in human gene therapy.

Authors:  Andrea Amalfitano; Robin J Parks
Journal:  Curr Gene Ther       Date:  2002-05       Impact factor: 4.391

3.  SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene.

Authors:  J A DeCaprio; J W Ludlow; J Figge; J Y Shew; C M Huang; W H Lee; E Marsilio; E Paucha; D M Livingston
Journal:  Cell       Date:  1988-07-15       Impact factor: 41.582

4.  Approach to establishing a liver targeting gene therapeutic vector using naturally occurring defective hepatitis B viruses devoid of immunogenic T cell epitope.

Authors:  Liqun Wang; Shuichi Kaneko; Masao Honda; Kenichi Kobayashi
Journal:  Virus Res       Date:  2002-05-10       Impact factor: 3.303

5.  Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression.

Authors:  Louay K Hallak; Jaime R Merchan; Chris M Storgard; Joseph C Loftus; Stephen J Russell
Journal:  Cancer Res       Date:  2005-06-15       Impact factor: 12.701

6.  Combination genetic therapy to inhibit HIV-1.

Authors:  David S Strayer; Francisco Branco; Julien Landré; Mohamad BouHamdan; Farida Shaheen; Roger J Pomerantz
Journal:  Mol Ther       Date:  2002-01       Impact factor: 11.454

7.  Efficient gene transfer to hematopoietic progenitor cells using SV40-derived vectors.

Authors:  D S Strayer; R J Pomerantz; M Yu; M Rosenzweig; M BouHamdan; S Yurasov; R P Johnson; H Goldstein
Journal:  Gene Ther       Date:  2000-05       Impact factor: 5.250

8.  Paradigms for conditional expression of RNA interference molecules for use against viral targets.

Authors:  David S Strayer; Mark Feitelson; Bill Sun; Alexey A Matskevich
Journal:  Methods Enzymol       Date:  2005       Impact factor: 1.600

9.  Transduction of long-term and mobilized peripheral blood-derived NOD/SCID repopulating cells by foamy virus vectors.

Authors:  Neil C Josephson; Grant Trobridge; David W Russell
Journal:  Hum Gene Ther       Date:  2004-01       Impact factor: 5.695

Review 10.  Kunjin RNA replication and applications of Kunjin replicons.

Authors:  Edwin G Westaway; Jason M Mackenzie; Alexander A Khromykh
Journal:  Adv Virus Res       Date:  2003       Impact factor: 9.937

View more
  3 in total

1.  Pseudovirions as vehicles for the delivery of siRNA.

Authors:  Paul E Lund; Ryan C Hunt; Michael M Gottesman; Chava Kimchi-Sarfaty
Journal:  Pharm Res       Date:  2009-12-09       Impact factor: 4.200

2.  Methods, potentials, and limitations of gene delivery to regenerate central nervous system cells.

Authors:  Arvind Kumar; Tryambak D Singh; Santosh K Singh; Satya Prakash
Journal:  Biologics       Date:  2009-07-13

Review 3.  Current approaches to enhance CNS delivery of drugs across the brain barriers.

Authors:  Cui-Tao Lu; Ying-Zheng Zhao; Ho Lun Wong; Jun Cai; Lei Peng; Xin-Qiao Tian
Journal:  Int J Nanomedicine       Date:  2014-05-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.